CML Treatment Market Growth Driven by Increasing Incidence
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Anticipated Rise In Market Value Of The Chronic Myeloid Leukemia (CML) Treatment Market During The Forecast Period?
The chronic myeloid leukemia (CML) treatment market has demonstrated substantial growth in recent years. It is projected to expand from $8.64 billion in 2025 to $9.23 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.8%. Historically, this growth can be attributed to factors such as improved diagnostic accuracy for hematological cancers, wider availability of first-generation TKIs, increased awareness of CML, the expansion of oncology treatment centers, and enhanced patient survival rates.
The chronic myeloid leukemia (cml) treatment market size is anticipated to experience robust expansion over the coming years. This market is projected to reach $12.17 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.2%. Factors contributing to this growth during the forecast period include the escalating development of innovative targeted agents, a rising acceptance of combination therapies, the broadening of precision oncology initiatives, an intensified focus on treatment compliance, and heightened investments in oncology research. Key trends expected in the forecast timeframe encompass the wider embrace of targeted therapy regimens, an increasing utilization of next-generation TKIs, an elevated concentration on molecular diagnostics, the enlargement of personalized treatment protocols, and a stronger emphasis on managing the disease over the long term.
Access Your Free Sample Report For In-Depth Market Analysis:
Which Strong Drivers Are Impacting The Chronic Myeloid Leukemia (CML) Treatment Market Growth?
The growing occurrence and widespread presence of the chronic myeloid leukemia (CML) patient demographic are projected to fuel expansion within the chronic myeloid leukemia (CML) treatment market in the foreseeable future. Chronic myeloid leukemia, also referred to as chronic myelogenous leukemia, is a form of cancer impacting the bone marrow and blood, distinguished by an excessive generation of immature white blood cells known as myeloid cells. Treatment for chronic myeloid leukemia (CML) aids in retarding the cancer’s advancement and preventing its progression to a later stage. As an illustration, data from March 2023, provided by the American Society of Clinical Oncology, a US-based professional organization for oncology physicians, indicates that in the United States, for 2023, approximately 35,730 persons (19,860 men and 15,870 women) are expected to receive a multiple myeloma diagnosis, with an anticipated 12,590 deaths from this illness in 2023 (7,000 males and 5,590 women). Consequently, the growing frequency and widespread occurrence of the chronic myeloid leukemia (CML) population are propelling the expansion of the chronic myeloid leukemia (CML) treatment market into the future.
Which Segment Categories Are Included In The Chronic Myeloid Leukemia (CML) Treatment Market Segment Analysis?
The chronic myeloid leukemia (cml) treatment market covered in this report is segmented –
1) By Type: Targeted Therapy, Chemotherapy, Radiation Therapy, Splenectomy, Stem Cell Transplant
2) By Drug Type: Tyrosine Kinase Inhibitors, Antimetabolites, Other Drug Types
3) By Application: Hospitals, Clinic, Other Applications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs), BCR-ABL Inhibitors, Monoclonal Antibody Therapy, Signal Transduction Inhibitors
2) By Chemotherapy: Alkylating Agents, Antimetabolites, Anthracyclines, Combination Chemotherapy Regimens
3) By Radiation Therapy: External Beam Radiation Therapy, Total Body Irradiation, Radioimmunotherapy
4) By Splenectomy: Partial Splenectomy, Total Splenectomy
5) By Stem Cell Transplant: Allogeneic Hematopoietic Stem Cell Transplant, Autologous Stem Cell Transplant
Which Trends Are Contributing To Changes In The Chronic Myeloid Leukemia (CML) Treatment Market?
Leading companies in the chronic myeloid leukemia (CML) treatment sector are actively pursuing strategic partnerships and collaborations to broaden their product portfolios, accelerate market entry, and expand their geographic footprint. Such alliances empower biotechnology firms to utilize specialized expertise in market access, regulatory guidance, and oncology commercialization, thereby bringing innovative therapies to patients more efficiently. For instance, in February 2023, Xspray Pharma, a Sweden-based biotechnology company, teamed up with EVERSANA, a US-based life sciences commercialization firm, to support the U.S. launch and commercialization of its product Dasynoc (XS004) for the treatment of chronic myeloid leukemia (CML) and acute lymphatic leukemia (ALL). Dasynoc, a new and distinct therapeutic option awaiting FDA approval and legal conditions, is projected to enter the $3.5 billion U.S. market for tyrosine kinase inhibitors. Through this partnership, Xspray Pharma will gain access to EVERSANA’s dedicated oncology-focused commercialization team, enabling a customized and efficient market entry strategy. Planned for launch in the second half of 2023, Dasynoc is anticipated to significantly improve treatment options for patients with CML and ALL in the United States.
Who Are The Active Companies Shaping The Chronic Myeloid Leukemia (CML) Treatment Market?
Major companies operating in the chronic myeloid leukemia (cml) treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Eisai Co. Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Incyte Corporation, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Amneal Pharmaceuticals LLC, Lupin Limited, Innovent Biologics Inc., Glenmark Pharmaceuticals Limited, Il-Yang Pharmaceutical Co. Ltd., Accord Healthcare Inc., ARIAD Pharmaceuticals Inc., Orca Bio, Bio-Path Holdings Inc.
Get The Full Chronic Myeloid Leukemia (CML) Treatment Market Report:
Which Region Has The Greatest Market Share In The Chronic Myeloid Leukemia (CML) Treatment Market?
North America was the largest region in the chronic myeloid leukemia (CML) treatment market in 2025. The regions covered in the chronic myeloid leukemia (cml) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Chronic Myeloid Leukemia (CML) Treatment Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Chronic Myeloid Leukemia (CML) Treatment Market 2026, By The Business Research Company
Leukemia Therapeutics Market Report 2026
https://www.thebusinessresearchcompany.com/report/leukemia-therapeutics-global-market-report
Chronic Myeloid Leukemia Treatment Market Report 2026
Chronic Myeloid Leukemia Treatment Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
